MAIA reports Phase 3 THIO enrolling on pace in 3rd-line NSCLC

On 22 September 2026, MAIA Biotechnology said enrollment in its pivotal Phase 3 THIO-104 trial is moving fast enough to keep the program advancing toward regulatory milestones ^[1]. The release carried momentum language, not a number: MAIA disclosed no current enrollment count against the trial's 300-patient target ^[1][2]. The registry lists THIO-104 (NCT06908304) as recruiting, testing THIO (ateganosine) sequenced with cemiplimab against investigator-choice chemotherapy in third-line advanced or metastatic NSCLC, with overall survival as the primary endpoint and a primary completion date of 31 July 2027 ^[2].

Why it matters

THIO is a mechanistic outlier. MAIA describes it as a first-in-class telomere-targeting agent — 6-thio-2'-deoxyguanosine, preferentially incorporated into the telomeres of telomerase-positive cancer cells, triggering telomere uncapping, DNA damage, cGAS/STING innate-immune activation and cell death — given ahead of the PD-1 inhibitor cemiplimab in patients who progressed on checkpoint inhibitors ^[3]. That places it in the thin third-line NSCLC setting, where investigator-choice chemotherapy remains the comparator ^[2], and on a target class distinct from the HER2, EGFR exon 20, CTLA-4 and KRAS G12C programs that have dominated recent NSCLC newsflow. FDA granted ateganosine Fast Track designation in third-line NSCLC ^[4].

The read on the event

A recruitment-pace update is a soft catalyst — it confirms the trial is live, not that it will read out well. The hard facts behind it: the Phase 3 is registry-confirmed and OS-powered ^[2], and MAIA said in April that its $33M March 2026 public offering would fully fund THIO-104 through completion ^[4]. Against that, the company suspended and terminated its H.C. Wainwright at-the-market facility on 14 May 2026, under which it had raised about $5.68M since March 2025 ^[7]. Whether the ATM wind-down changes the "fully funded" math is not resolvable from the public record supplied here.

The supporting program

The Phase 2 THIO-101 trial (NCT05208944) is active but no longer recruiting, with 227 patients enrolled and no results yet posted ^[3]. MAIA dosed its first U.S. patient in that trial on 16 September 2026 ^[8], having activated its first U.S. site (Summit Medical Group, NJ) in April under a $2.3M NIH grant ^[6], with trade press reporting two further U.S. site activations in June 2026 ^[10][11]. In March, MAIA reported overall survival beyond two years for eight THIO-101 patients in an ELCC poster ^[5]. The company also presented at the IRT 2026 meeting on 10 September 2026 ^[9].

What to watch next

• Enrollment disclosure: any hard THIO-104 count against the 300 target — likely in a subsequent 8-K or quarterly update — would convert today's pace claim into something a competitor can model. None is in the current record.
• Primary completion 31 July 2027 ^[2]: the date governing the OS analysis; a soft pace update now says nothing about interim timing.
• Cash runway: a later filing reconciling the terminated ATM ^[7] with the "fully funds" claim ^[4] is the one that matters for whether Phase 3 reaches readout on current cash.

The now-what

For an operator tracking third-line NSCLC:

1. Treat this as a live pivotal, not a data event — put THIO-104's July 2027 completion on the long-range calendar and revisit at the next enrollment or cash disclosure.
2. If your program uses chemotherapy as its third-line comparator or control, note that MAIA is building an OS dataset against exactly that comparator in a checkpoint-refractory population ^[2].
3. For BD, the differentiated telomere/cGAS-STING mechanism ^[3] is the diligence hook — but with no posted Phase 2 results ^[3] and no Phase 3 efficacy, it is a watch-item, not an actionable asset yet.

What Prognyx could not verify

The registry status reflects snapshots dated 12 January 2026 for the Phase 3 and 16 September 2026 for the Phase 2 ^[2][3], not a live pull; status should be re-checked before acting. And the public filings here do not settle whether the May 2026 ATM termination ^[7] affects the April "fully funded" position ^[4].

Verdict: Low-to-moderate threat, slow clock. Nothing here forces a competitor's hand before an enrollment or cash disclosure; the real signal is the OS readout gated to the 31 July 2027 primary completion.